Avis Budget Group, Inc.

Avis Budget Group, Inc.

CAR

$105.67

Updated: 24/09/2026, 14:10:13

Market Cap
$3.73B
Sector
Industrials
Industry
Rental & Leasing Services
Country
US
Stock valuation chart
One-year closing share-price history for CAR
Company Profile

Avis Budget Group, Inc. is a prominent global provider of diverse mobility solutions, delivering vehicle rental services for both cars and trucks, alongside car-sharing options, to a broad clientele encompassing businesses and individual consumers. The company's brand portfolio includes Avis, which focuses on providing premium vehicle rentals and comprehensive mobility solutions to both commercial and leisure segments of the travel industry. For truck and cargo van rentals, the Budget Truck brand operates a fleet of approximately 20,000 vehicles. These are available for local and one-way hire through a vast network of roughly 465 dealer-operated and 385 company-owned locations across the continental United States, catering to both residential and light commercial needs. Furthermore, the company manages Zipcar, a well-known car-sharing network, and an array of other car rental brands such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. Beyond its core vehicle offerings, Avis Budget Group supplies an extensive range of supplementary products and services. These include various optional insurance covers, such as supplemental liability, personal accident, personal effects protection, emergency sickness, and insurance for automobile towing and cargo. Customers can also access fuel service plans, roadside assistance, electronic toll collection, curbside delivery, and rentals for items like tablets, satellite radio access, portable navigation units, and child safety seats. For moving purposes, the company provides automobile towing equipment and essential accessories such as hand trucks, furniture pads, and moving supplies. Additionally, corporate clients benefit from a Business Intelligence solution, an online platform designed for managing their corporate travel needs. With a significant international presence, Avis Budget Group, Inc. operates at approximately 10,400 locations across the globe. Founded in 1946 and headquartered in Parsippany, New Jersey, the company was formerly named Cendant Corporation before adopting its current name in September 2006.

USD
NASDAQ
CEO: Brian J. Choi
Employees: 21,000
https://www.avisbudgetgroup.com
Asset Summaries
Latest generated summaries for CAR

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for CAR.
Share price
$105.67
Market cap
$3.73B
Exchange
NASDAQ
Currency
USD
CEO
Brian J. Choi
Employees
21,000
IPO date
14/09/1983
Beta
1.902
Last dividend
$0.00
Day range
$104.95 – $110.75
52-week range
$85.96 – $847.70
1-day performance
-1.91%
1-year performance
22.93%
Current drawdown (1Y)
-87.53%
CIK
0000723612
CUSIP
053774105
ISIN
US0537741052
Created
07/12/2025, 03:11:23
Last update
24/09/2026, 14:10:13

Track Avis Budget Group, Inc. with an AI analyst

See which prediction-market events move CAR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CAR from your Railway `news_articles` table.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewsWire • STOCK • 15/06/2026, 10:00:00

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewsWire • STOCK • 14/06/2026, 05:15:00

Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Seeking Alpha • STOCK • 13/06/2026, 14:23:38

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewsWire • STOCK • 09/06/2026, 09:00:00

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears

MarketBeat • STOCK • 09/06/2026, 08:06:02

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Accesswire • STOCK • 04/06/2026, 10:40:00

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

GlobeNewsWire • STOCK • 02/06/2026, 11:30:00

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

PRNewsWire • STOCK • 01/06/2026, 09:00:00

CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities

Zacks Investment Research • STOCK • 28/05/2026, 16:55:35

Avis Budget Group Announces Pricing of $300 Million of Senior Notes

GlobeNewsWire • STOCK • 27/05/2026, 19:21:00

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

GlobeNewsWire • STOCK • 27/05/2026, 09:45:00

Avis Budget Group Announces Intention to Offer $300 Million of Senior Notes

GlobeNewsWire • STOCK • 27/05/2026, 09:30:00